BioPorto A/S

Copenhagen Stock Exchange BIOPOR.CO

BioPorto A/S EBIT Margin for the year ending December 31, 2023: -195.64%

BioPorto A/S EBIT Margin is -195.64% for the year ending December 31, 2023, a 29.56% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

BioPorto A/S EBIT Margin for the year ending December 31, 2022 was -277.74%, a -7.28% change year over year.
BioPorto A/S EBIT Margin for the year ending December 31, 2021 was -258.90%, a 8.96% change year over year.
BioPorto A/S EBIT Margin for the year ending December 31, 2020 was -284.39%, a -2.59% change year over year.
BioPorto A/S EBIT Margin for the year ending December 31, 2019 was -277.20%, a -73.76% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Copenhagen Stock Exchange: BIOPOR.CO

BioPorto A/S

CEO	Mr. Peter Moerch Eriksen B.B.A., BBA
IPO Date	Jan. 13, 2000
Location	Denmark
Headquarters	Tuborg Havnevej 15, st.
Employees	27
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

Key trends

Past 5 years